ERBB2 and breast cancer: For this reason, the aim is to provide the most effective therapy in the neoadjuvant setting, such as dose-dense chemotherapy regimens [13,14,15], dual anti-HER2 therapy in HER2 positive BC [16,17], platinum salts added in selected patients in TNBC [18,19,20,21,22], and, soon, administration of an immunotherapy and chemotherapy combination, which increases the likelihood of achieving pCR [23].